Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.24.1.1.u2
Segment Information (Tables)
3 Months Ended
Mar. 31, 2024
Segment Information  
Schedule of Segment Information

Pharmaceutical

    

and

Dermatology

Biotechnology

Products

Product

Three Months Ended March 31, 2024

    

Sales

    

Development

    

Consolidated

Net revenue

$

13,030

$

$

13,030

Cost of goods - product revenue

 

(6,816)

 

 

(6,816)

Research and development

 

(7,884)

 

(16,955)

 

(24,839)

Selling, general and administrative

(8,420)

(9,521)

(17,941)

Other expense

 

(352)

 

(2,105)

 

(2,457)

Segment loss

$

(10,442)

$

(28,581)

$

(39,023)

Pharmaceutical

and

Dermatology

Biotechnology

Products

Product

Three Months Ended March 31, 2023

    

Sales

    

Development

    

Consolidated

Net revenue

$

12,213

$

216

$

12,429

Cost of goods - product revenue

 

(6,449)

 

 

(6,449)

Research and development

 

(2,033)

 

(37,473)

 

(39,506)

Selling, general and administrative

 

(13,291)

(12,050)

(25,341)

Other expense

(575)

 

4,297

 

3,722

Segment loss

$

(10,135)

$

(45,010)

$

(55,145)

Pharmaceutical

    

and

($ in thousands)

Dermatology

Biotechnology

Products

Product

March 31, 2024

    

Sales

    

Development

    

Total Assets

Intangible assets, net

$

19,473

$

$

19,473

Tangible assets

47,098

98,074

145,172

Total segment assets

$

66,571

$

98,074

$

164,645

Pharmaceutical

    

and

($ in thousands)

Dermatology

Biotechnology

Products

Product

December 31, 2023

    

Sales

    

Development

    

Total Assets

Intangible assets, net

$

20,287

$

$

20,287

Tangible assets

56,561

90,678

147,239

Total segment assets

$

76,848

$

90,678

$

167,526